Alizapride

Revision as of 15:52, 27 September 2011 by Matt Pijoan (talk | contribs) (Protected "Alizapride": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Alizapride
File:Alizapride.svg
Clinical data
Routes of
administration
Oral, intramuscular, intravenous
ATC code
Pharmacokinetic data
Elimination half-life3 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC16H21N5O2
Molar mass315.37 g/mol

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Alizapride is a dopamine antagonist with prokinetic and antiemetic effects used in the treatment of nausea and vomiting, including postoperative nausea and vomiting. It is structurally related to metoclopramide.[1]

Alizapride is marketed under various trade names including Plitican, Superan and Vergentan.[2]

References

  1. Bleiberg H, Gerard B, Dalesio O, Crespeigne N, Rozencweig M (1988). "Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial". Cancer Chemother Pharmacol. 22 (4): 316–20. PMID 3048762.
  2. Template:Fr icon "Alizapride Chlorhydrate". BIAM. June 2 1997. Retrieved 2007-08-14. Check date values in: |date= (help)


Template:Drugs for functional gastrointestinal disorders